Carvykti

{
  "id": "MLC-T-ONC-001478",
  "term": "Carvykti",
  "field": "Oncology and biomedicine",
  "definition": "A treatment used for adults with multiple myeloma that came back or did not get better after treatment with at least one line of anticancer therapy that included a proteasome inhibitor and an immunomodulating agent. It is used in patients whose cancer did not respond to treatment with lenalidomide. Carvykti is made using a patient’s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Carvykti binds to a protein called BCMA, which is found on myeloma cells and some types of immune cells. This helps the body’s immune system kill cancer cells. Carvykti is a type of cellular immunotherapy called CAR T-cell therapy. Also called ciltacabtagene autoleucel.",
  "synonyms": [
    "ciltacabtagene autoleucel"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/carvykti/"
}